Mebendazole
INDICATIONS
FDA
Note: The Vermox brand was withdrawn from the U.S. market in 2011; mebendazole subsequently returned to the U.S. market as Emverm (mebendazole 100 mg chewable tablet), FDA-approved in 2016. FDA-approved Vermox 500 mg chewable tablets are not commercially available in the U.S., but they are distributed as part of a global product donation program (led by Johnson & Johnson in partnership with the WHO) to endemic areas burdened by soil-transmitted helminths (STH). U.S. 100-mg and historically approved 500-mg formulations have different FDA-approved indications, dosing regimens, and labeling.
- Enterobiasis (pinworm)
- Hookworm
- A. duodenale and N. americanus
- Ascariasis (roundworm)
- Trichuriasis (whipworm)
NON-FDA APPROVED USES
- Established treatment options
- Capillariasis (intestinal)
- CDC preferred
- Trichinosis
- Capillariasis (intestinal)
- Alternative therapies:
- Echinococcus (cystic)
- Mansonella perstans
- Toxocariasis
- Trichostrongyliasis
- Historical or exceptional use:
- Strongyloidiasis
- No longer recommended because of reliable alternatives.
- Strongyloidiasis
There's more to see -- the rest of this topic is available only to subscribers.

Johns Hopkins ABX Guide

